FDA Approves Tocilizumab for Treatment of Rheumatoid Arthritis

On January 8, 2010, the U.S. Food and Drug Administration approved tocilizumab (to be marketed under the trade name of Actemra) for the treatment of patients with moderate to severe rheumatoid arthritis who have had inadequate clinical responses to treatment with TNF inhibitors.  Tocilizumab is a humanized monoclonal antibody directed against the receptor for IL-6, […]